On 11/7/24, Haemonetics Corp (NYSE: HAE) stock enjoyed a major increase of 10.7%, closing at $86.53. Moreover, this advance was accompanied by exceptionally high trading volume at 259% of normal. The stock has performed in line with the market over the last nine months and has risen 20.1% during the last week.
Current PriceTarget Research Rating
HAE’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Haemonetics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Haemonetics has a neutral Power Rating of 41 and a slightly negative Appreciation Score of 38, producing the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment